The FDA has granted quick monitor designation to the prostate-specific membrane antigen (PSMA)–focused radiopharmaceutical 225Ac-FL-020 for the therapy of sufferers with metastatic castration-resistant...
The ELEVATE trial (NCT05563220) is an ongoing part 1b/2 examine investigating elacestrant (Oserdu) mixed with numerous focused therapies for sufferers with endocrine rececptor-positive...